David A. Siegel Prometheus Biosciences, Inc. Transaction History

Two Sigma Advisers, LP

  • $42.5 Billion
  • Q1 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
SELL
$103.46 - $126.29 $4.77 Million - $5.82 Million
-46,100 Reduced 34.12%
89,000 $9.55 Million
Q4 2022

Feb 14, 2023
BUY
$36.06 - $117.21 $183,906 - $597,771
5,100 Added 3.92%
135,100 $14.9 Million
Q3 2022

Nov 14, 2022
BUY
$28.17 - $59.01 $2.96 Million - $6.2 Million
105,000 Added 420.0%
130,000 $7.67 Million
Q2 2022

Aug 15, 2022
BUY
$22.39 - $38.94 $559,750 - $973,500
25,000 New
25,000 $706,000

Others Institutions Holding RXDX

# of Institutions
2
Shares Held
29.6K
Call Options Held
0
Put Options Held
0
View Full List

About Prometheus Biosciences, Inc.

RXDX Quotes by TradingView
  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email